Prospective study of a web-mediated management of febrile neutropenia related to chemotherapy (Bioconnect)
We aimed to investigate whether patient self-evaluated symptoms transmitted via Internet is feasible between planned visits to provide an early management of fever and neutropenia induced by chemotherapy, and if it can reduce hospitalizations for severe neutropenia.
Patients who received a chemotherapy regimen with an overall risk of febrile neutropenia ≥ 20% had to report daily temperature between physician planned visits using a web application. Fever and clinical signs of seriousness were reported to the physician (if some criteria were fulfilled in a specific algorithm) via automatic email notifications by the web application. Patients could be hospitalized quickly or could take over at home, make blood count, and take predefined oral antibiotics if indicated. Primary outcome was patient’s compliance and satisfaction. The number and the cost of hospitalization were also assessed and compared with an historical cohort of patients with similar clinical conditions and treatment.
Among the 41 patients included, 36 (87.8%) used the web application with 88% of daily compliance and 90% (28/33) of satisfaction. One patient (2.7%) had planned hospitalization after the web application alert. In the historical cohort, the rate of unplanned hospitalization for febrile neutropenia was 17% (6 patients) and 2.7% (1 patient) in users of the web application cohort. The cumulative cost of hospitalization for neutropenia was USD 28,827 in the historical cohort and USD 6563 in the web application cohort.
Web-mediated follow-up of febrile neutropenia is feasible. It led to high patient satisfaction, high compliance, and a possible reduction of the number and the cost of hospitalizations.
Keywordse-health Neutropenia Chemotherapy Clinical trial
We thank the patients and their families for their participation in this study, as well as investigators, promotor: Integrated Center for Oncology (ICO, Angers, France), Anne-Lise Septans for statistical analysis, Magali Balavoine for trial monitoring, and sponsors: CHUGAI PHARMA France and SIVAN Innovation Ltd. for financial sponsorship.
This work was supported by CHUGAI PHARMA France and SIVAN Innovation Ltd.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 3.Bakitas MA, Tosteson TD, Li Z, Lyons KD, Hull JG, Li Z, Dionne-Odom JN, Frost J, Dragnev KH, Hegel MT, Azuero A, Ahles TA (2015) Early versus delayed initiation of concurrent palliative oncology care: patient outcomes in the ENABLE III randomized controlled trial. J Clin Oncol 33:1438–1445CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Denis F, Yossi S, Septans AL et al (2015) Improving survival in patient treated for a lung cancer using self-evaluated symptoms reported via a web-application. Am J Clin OncolGoogle Scholar
- 8.Denis F, Lethrosne C, Pourel N, Molinier O, Pointreau Y, Domont J, Bourgeois H, Senellart H, Trémolières P, Lizée T, Bennouna J, Urban T, el Khouri C, Charron A, Septans AL, Balavoine M, Landry S, Solal-Céligny P, Letellier C (2017) Randomized trial comparing a web-mediated follow-up to routine surveillance in lung cancer patients. J Natl Cancer Inst 109(9). https://doi.org/10.1093/jnci/djx029
- 10.Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis 52(4):e56–e93CrossRefPubMedGoogle Scholar
- 13.Tai E, Guy GP, Dunbar A, Richardson LC (2017) Cost of cancer-related neutropenia or fever hospitalizations, United States, 2012. J Oncol Pract. https://doi.org/10.1200/JOP.2016.019588
- 14.(2012) National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Myeloid growth factors. v1Google Scholar